Silexion Therapeutics Corp
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
SLXN$0.12-14.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| 2024 | 2023 | |
|---|---|---|
| Assets | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $1,187 | $4,595 |
| Restricted cash | 35 | 25 |
| Prepaid expenses | 966 | 335 |
| Other current assets | 62 | 24 |
| TOTAL CURRENT ASSETS | 2,250 | 4,979 |
| NON-CURRENT ASSETS: | ||
| Restricted cash | 48 | 25 |
| Long-term deposit | 5 | 5 |
| Property and equipment, net | 30 | 49 |
| Operating lease right-of-use asset | 530 | 198 |
| TOTAL NON-CURRENT ASSETS | 613 | 277 |
| TOTAL ASSETS | $2,863 | $5,256 |
CONSOLIDATED BALANCE SHEETS
| 2024 · 2023 | |||
|---|---|---|---|
| Liabilities and redeemable convertible preferred shares, net of capital deficiency | |||
| CURRENT LIABILITIES: | |||
| Trade payables | $929 | $319 | |
| Current maturities of operating lease liability | 158 | 112 | |
| Warrants to preferred shares (including $0 and $186 due to related party, as of December 31, 2024 and December 31, 2023, respectively) | - | 200 | |
| Employee related obligations | 642 | 207 | |
| Accrued expenses and other accounts payable | 788 | 1,358 | |
| Private warrants to purchase ordinary shares (including $1 and $0 due to related party, as of December 31, 2024 and December 31, 2023, respectively) | 2 | - | |
| Underwriters Promissory Note | 1,004 | - | |
| TOTAL CURRENT LIABILITIES | 3,523 | 2,196 | |
| NON-CURRENT LIABILITIES: | |||
| Long-term operating lease liability | 368 | 59 | |
| Related Party Promissory Note | 2,961 | - | |
| TOTAL NON-CURRENT LIABILITIES | $3,329 | $59 | |
| TOTAL LIABILITIES | $6,852 | $2,255 | |
| COMMITMENTS AND CONTINGENT LIABILITIES (Note 7) | |||
| Convertible Series A Preferred Shares (NIS 0.09 par value, 0 and 56,667 shares authorized as of December 31, 2024 and 2023, 0 and 43,121 shares issued and outstanding as of December 31, 2024 and 2023); | |||
| Convertible Series A-1 Preferred Shares (NIS 0.09 par value per share, 0 and 13,334 shares authorized as of December 31, 2024 and 2023, 0 and 10,136 shares issued and outstanding as of December 31, 2024 and 2023); | |||
| Convertible Series A-2 Preferred Shares (NIS 0.09 par value per share, 0 and 22,223 shares authorized as of December 31, 2024 and 2023, 0 and 5,051 shares issued and outstanding as of December 31, 2024 and 2023); | |||
| Convertible Series A-3 Preferred Shares (NIS 0.09 par value per share, 0 and 8,889 shares authorized as of December 31, 2024 and 2023, 0 and 7,037 shares issued and outstanding as of December 31, 2024 and 2023); | |||
| Convertible Series A-4 Preferred Shares (NIS 0.09 par value per share 0 and 90,556 and shares authorized as of December 31, 2024 and 2023, respectively 0 and 2,413** shares issued and outstanding as of December 31, 2024 and 2023, respectively); | |||
| TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES | - | 15,057 | |
| CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS | - | 3,420 | |
| TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS | $ | - | $18,477 |
| CAPITAL DEFICIENCY: Ordinary shares ($0.0009 par value per share, 22,222,222 shares authorized as of December 31, 2024 and 2023; 1,848,711**** and 97,120 shares issued and outstanding as of December 31, 2024 and 2023, respectively) | 2 | * | |
| Additional paid-in capital | 39,263 | 11,335 | |
| Accumulated deficit | (43,254) | (26,811) | |
| TOTAL CAPITAL DEFICIENCY | $(3,989) | $(15,476) | |
| TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY | $(3,989) | $3,001 | |
| TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTEREST, NET OF CAPITAL DEFICIENCY | $2,863 | $5,256 | |
**Net of 13,458 treasury shares held by the Chinese Subsidiary as of December 31, 2023
*** All share amounts have been retroactively adjusted to reflect a 1-for-9 reverse share split as discussed in Note 1h
**** Net of 421 treasury shares held by the Company as of December 31, 2024
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.